Diabetes, Vol 43, Issue 3 369-374, Copyright © 1994 by American Diabetes Association

ARTICLES

Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients

N Jabri, DS Schalch, SL Schwartz, JS Fischer, MS Kipnes, BJ Radnik, NJ Turman, VS Marcsisin and HP Guler
Clinical Science Center, University of Wisconsin, Madison 53792.

Data from studies in diabetic rodents and evidence from clinical situations of severe resistance to insulin suggest that insulin-like growth factor I (IGF-I) is able to at least partly overcome insulin resistance. To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals who had been treated previously with high doses of insulin (> 0.7 U.kg-1 x day-1). Four patients exhibited comparable or enhanced, whereas three had diminished, blood glucose control on rhIGF-I relative to that while on twice daily NPH insulin during the six-week control period. The occurrence of adverse effects in all patients compelled us to discontinue rhIGF-I administration before completing the 8-week treatment period. These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site. We conclude that the frequency and severity of side effects associated with administering high-dose subcutaneous rhIGF-I to obese insulin-resistant diabetic patients make it an unacceptable therapeutic agent for these patients despite its ability to produce reasonable blood glucose control in approximately 50% of them.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. R. Clemmons, M. Sleevi, G. Allan, and A. Sommer Effects of Combined Recombinant Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein-3 in Type 2 Diabetic Patients on Glycemic Control and Distribution of IGF-I and IGF-II among Serum Binding Protein Complexes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2652 - 2658. [Abstract] [Full Text] [PDF]

				M. G. Jeschke, U. Bolder, D. H. Chung, R. Przkora, U. Mueller, J. C. Thompson, S. E. Wolf, and D. N. Herndon Gut Mucosal Homeostasis and Cellular Mediators after Severe Thermal Trauma and the Effect of Insulin-Like Growth Factor-I in Combination with Insulin-Like Growth Factor Binding Protein-3 Endocrinology, January 1, 2007; 148(1): 354 - 362. [Abstract] [Full Text] [PDF]

				P. Delafontaine, Y.-H. Song, and Y. Li Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 435 - 444. [Abstract] [Full Text]

				S. Zaina, L. Pettersson, A. B. Thomsen, C.-M. Chai, Z. Qi, J. Thyberg, and J. Nilsson Shortened Life Span, Bradycardia, and Hypotension in Mice with Targeted Expression of an Igf2 Transgene in Smooth Muscle Cells Endocrinology, June 1, 2003; 144(6): 2695 - 2703. [Abstract] [Full Text] [PDF]

				E. J. Su, C. L. Cioffi, S. Stefansson, N. Mittereder, M. Garay, D. Hreniuk, and G. Liau Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1429 - H1440. [Abstract] [Full Text] [PDF]

				S. Boonen, C. Rosen, R. Bouillon, A. Sommer, M. McKay, D. Rosen, S. Adams, P. Broos, J. Lenaerts, J. Raus, et al. Musculoskeletal Effects of the Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1593 - 1599. [Abstract] [Full Text] [PDF]

				P. H. Wang Roads to Survival : Insulin-Like Growth Factor-1 Signaling Pathways in Cardiac Muscle Circ. Res., March 30, 2001; 88(6): 552 - 554. [Full Text]

				K. Cusi and R. DeFronzo Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3077 - 3084. [Abstract] [Full Text]

				D. R. Clemmons, A. C. Moses, M. J. McKay, A. Sommer, D. M. Rosen, and J. Ruckle The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence for in VivoBiological Activity J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1518 - 1524. [Abstract] [Full Text]

				M. G. Jeschke, R. E. Barrow, H. K. Hawkins, M. T. Chrysopoulo, J. R. Perez-Polo, and D. N. Herndon Effect of Multiple Gene Transfers of Insulinlike Growth Factor I Complementary DNA Gene Constructs in Rats After Thermal Injury Arch Surg, October 1, 1999; 134(10): 1137 - 1141. [Abstract] [Full Text] [PDF]

				L. E. Levitt Katz, R. J. Ferry Jr., C. A. Stanley, P. F. Collett-Solberg, L. Baker, and P. Cohen Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective {beta}-Cell Sulfonylurea Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3117 - 3124. [Abstract] [Full Text]

				A. Vijayan, S. C. Franklin, T. Behrend, M. R. Hammerman, and S. B. Miller Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure Am J Physiol Regulatory Integrative Comp Physiol, April 1, 1999; 276(4): R929 - R934. [Abstract] [Full Text] [PDF]

				M. Y. Donath, G. Sütsch, X.-W. Yan, B. Piva, H.-P. Brunner, Y. Glatz, J. Zapf, F. Follath, E. R. Froesch, and W. Kiowski Acute Cardiovascular Effects of Insulin-Like Growth Factor I in Patients with Chronic Heart Failure J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3177 - 3183. [Abstract] [Full Text]

				A. Cittadini, H. Stromer, D. E. Vatner, J. D. Grossman, S. E. Katz, R. Clark, J. P. Morgan, and P. S. Douglas Consequences of Growth Hormone Deficiency on Cardiac Structure, Function, and {beta}-Adrenergic Pathway: Studies in Mutant Dwarf Rats Endocrinology, December 1, 1997; 138(12): 5161 - 5169. [Abstract] [Full Text] [PDF]

				D. Le Roith Insulin-Like Growth Factors N. Engl. J. Med., February 27, 1997; 336(9): 633 - 640. [Full Text] [PDF]

				A. Cittadini, H. Stromer, S. E. Katz, R. Clark, A. C. Moses, J. P. Morgan, and P. S. Douglas Differential Cardiac Effects of Growth Hormone and Insulin-like Growth Factor1 in the Rat : A Combined In Vivo and In Vitro Evaluation Circulation, February 15, 1996; 93(4): 800 - 809. [Abstract] [Full Text]